Podium to Practice: Chicago 2025 – Lung: CheckMate 816
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
LBA8000 – Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
This program has been made possible through unrestricted support from Boehringer Ingelheim.
Studies/trials discussed:
LBA8000 – Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
199 Bay Street #4000
Toronto, ON M5L 1A9
©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.